Global Doxorubicin Market Report and Forecast 2024-2032

Global Doxorubicin Market Outlook

The global doxorubicin market size attained a value of USD 1,295.95 million in 2023 driven highly by the rising incidences of cancer across the globe. The market is anticipated to grow at a CAGR of 6.4% during the forecast period of 2024-2032 to attain a value of USD 2,264.98 million by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Breast Cancer Segment to Hold a Significant Market Share of the Market Over the Forecast Period

Doxorubicin finds its largest regional market in North America. The region is expected to retain its dominance over the global market in the coming years owing to the increase in cancer incidence and associated mortality rate. The United States registered the highest cancer rate and considerable deaths in 2020. Meanwhile, the regional market in the Asia Pacific is estimated to grow with healthy CAGR over the period owing to the highest mortality rate in China. In terms of application, the most prevalent cancers include breast cancer, prostate cancer, lung cancer, colon and rectum cancer, and skin melanoma. Hence, the segment of breast cancer is projected to account for the maximum use of the drug in the coming years. According to WHO, the number of breast cancer cases found in the year 2020 was around 2.26 million, which is about 11.7% of all the new cases registered that year.

Doxorubicin: Market Segmentation

Doxorubicin (C27H29NO11) is a medication for chemotherapy used in the treatment of various cancer diseases, including breast cancer, bladder cancer, lymphoma, and others. It is administered as an intravenous drug along with other chemotherapy agents and is sold under different brand names including Adriamycin, and Caelyx, among others.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The applications for doxorubicin include:

• Ovarian Cancer
• Multiple Myeloma
• Kaposi Sarcoma
• Leukaemia
• Bone Sarcoma
• Breast Cancer
• Endometrial Cancer
• Gastric Cancer
• Liver Cancer
• Kidney Cancer
• Other Cancer

The EMR report looks into the regional markets of doxorubicin like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rising Cancer Cases and Related Deaths to Bolster the Demand for Doxorubicin

The primary driver for the market growth of doxorubicin is the rising incidences of cancer across the globe. This increase can be attributed to the presence of carcinogens in day-to-day use products in the current lifestyle of people. According to the latest statistics provided by the Union for International Cancer Control (UICC), the number of cancer cases has risen to 19.3 million and 10 million cancer related deaths in 2020. This rise is expected to continue in the forthcoming years, providing lucrative opportunities for demand growth of doxorubicin. Additionally, supportive actions from the government for technological progress in clinical diagnostics and therapeutics such as intravenous free therapy and digital microfluidics for biochemical analysis is expected to boost the market growth of the drug over the forecast period. However, it is noteworthy that certain side effects, such as hand-foot syndrome, typhlitis, heart failure, among others, can potentially impede the growing demand.

Key Industry Players in the Global Doxorubicin Market

The report presents a detailed analysis of the following key players in the global doxorubicin market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• Pfizer Inc.
• Sun Pharmaceutical Industries Limited
• Cipla, Inc.
• Cadila Pharmaceuticals Ltd.
• Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report